Guideline for the management of knee and hip osteoarthritis

Acronyms

Acronyms and abbreviations used throughout this guideline

 
 

ACR

American College of Rheumatology

AIHW

Australian Institute of Health and Welfare

ASU

avocado/soybean unsaponifiables

 

BMI

body mass index

 

CALD

culturally and linguistically diverse

CBT

cognitive behavioural therapy

CENTRAL

Cochrane Database of Systematic Reviews and Cochrane Central Register  of Controlled Trials

CI

confidence interval

CINAHL

Cumulative Index to Nursing and Allied Health Literature

COI

conflict of interest

COX

cyclooxygenase

COX-2

cyclooxygenase-2

CRP

C-reactive protein

CT

computed tomography

 

DALYs

disability-adjusted life-years

DHA

docosahexaenoic acid

DMOADs

disease-modifying osteoarthritis drugs

DMSO

dimethylsulfoxide

 

EMA

European Medicines Agency

EPA

eicosapentaenoic acid

ESR

erythrocyte sedimentation rate

 

FGF

fibroblast growth factor

 

GP

general practitioner

GRADE

Grading of Recommendations Assessment, Development and Evaluation

 

HANDI

Handbook of non-drug interventions

HOOS

Hip Disability and Osteoarthritis Outcome Score

 

ICTRP

International Clinical Trials Registry Platform

IgG2

immunoglobulin G2

IL-1

interleukin-1

IPDAS

International Patient Decision Aids Standards

 

KOOS

Knee Injury and Osteoarthritis Outcome Score

 

MBS

Medicare Benefits Schedule

MD

mean difference

MRI

magnetic resonance imaging

MSC

mesenchymal stem cell

MSM

methylsulfonylmethane

 

NATSIHS

National Aboriginal and Torres  Strait Islander Health Survey

NGF

nerve growth factor

NHMRC

National Health and Medical  Research Council

NICE

National Institute for Health  and Care Excellence

NPRS

Numeric Pain Rating Scale

NSAID

nonsteroidal anti-inflammatory drug

 

OA

osteoarthritis

OARSI

Osteoarthritis Research Society International

OR

odds ratio

 

p75NTR

75 kDa neurotrophin receptor

PBS

Pharmaceutical Benefits Scheme

PG

prostaglandin

PHN

Primary Health Network

PICO

patient/population/problem, intervention, comparison/control, outcome

PPI

proton-pump inhibitor

PRAC

Pharmacovigilance Risk Assessment Committee

PRP

platelet-rich plasma

 

RACGP

The Royal Australian College  of General Practitioners

RCT

randomised controlled trial

RR

relative risk

 

SES

socioeconomic status

SMD

standardised mean difference

SNRI

serotonin and norepinephrine  reuptake inhibitor

 

TEAE

treatment-emergent adverse event

TENS

transcutaneous electrical nerve stimulation

TGA

Therapeutic Goods Administration

TNF-alpha

tumour necrosis factor alpha

TrkA

tyrosine kinase receptor

TRPV1

Transient Receptor Potential Vanilloid 1

 

VAS

Visual Analog Scale

 

WHO

World Health Organization

WOMAC 

Western Ontario and McMaster  Universities Osteoarthritis Index

Advertising